<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01956903</url>
  </required_header>
  <id_info>
    <org_study_id>CSM/EICH2010</org_study_id>
    <secondary_id>2010-020947-11</secondary_id>
    <nct_id>NCT01956903</nct_id>
  </id_info>
  <brief_title>Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell.</brief_title>
  <acronym>CSM/EICH2010</acronym>
  <official_title>Phase 1/2 Study of Treatment of Refractory Acute Graft-Versus-Host Disease After First Line Therapy by Sequential Infusion of Expanded In-Vitro Allogenic Mesenchymal Stem Cell</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol de trasplantes hematopoyeticos y terapia celular</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Espanol de trasplantes hematopoyeticos y terapia celular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of sequential infusion of&#xD;
      allogenic mesenchymal stem cells (MSC) expanded &quot;in vitro&quot; in treating patients with acute&#xD;
      graft-versus-host disease refractory to first-line therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Ethical considerations:&#xD;
&#xD;
             -  The study will be conducted in accordance with the requirements expressed in the&#xD;
                Declaration of Helsinki (Hong Kong revision, September 1989) and following the&#xD;
                recommendations of the Good Clinical Practice of the Clinical Trials (document&#xD;
                111/3976/88, July 1990 ) and Spanish legislation (Royal Decree 561/1993, published&#xD;
                in April 16th Official State Bulletin &quot;BOE&quot;; May 13th, 1993) laying down the&#xD;
                requirements for conducting clinical drug trials.&#xD;
&#xD;
             -  Every subject will receive a written document called &quot;Patient Information Sheet&quot;&#xD;
                that contains information about the following aspects of clinical trial: a) Aim of&#xD;
                the study, methodology, study treatment and alternative therapies, expected&#xD;
                benefits for himself or society, risks of the study and possible adverse events,&#xD;
                number of visits and additional tests.&#xD;
&#xD;
                b) Voluntary nature of their participation and ability to withdraw at any time,&#xD;
                without thereby altering the doctor-patient relationship.&#xD;
&#xD;
                c) People who have access to the data of the volunteer and how they maintain the&#xD;
                confidentiality of the data.&#xD;
&#xD;
                d) How to contact with the investigator if necessary.&#xD;
&#xD;
             -  The investigator will obtain the informed consent of the subject or, failing that,&#xD;
                from a legal representative. The subject is preferably expressed written consent&#xD;
                or, alternatively, orally to the research team independent witnesses who declare in&#xD;
                writing under its responsibility.&#xD;
&#xD;
             -  The person participating in the clinical trial or his representative may revoke the&#xD;
                consent at any time.&#xD;
&#xD;
        2. Data Access:&#xD;
&#xD;
             -  In order to ensure the confidentiality of the trial data, only have access to them,&#xD;
                the researcher and his team, the test monitor and the Clinical Research Ethics&#xD;
                Committee of the corresponding center or purposes under test and relevant health&#xD;
                authorities.&#xD;
&#xD;
             -  Protection of data: The content of the data collection forms and the documents&#xD;
                generated during the study, will be protected from unauthorized uses by people&#xD;
                outside the research and, therefore, will be considered strictly confidential and&#xD;
                will not be disclosed to third parties except to those specified in the preceding&#xD;
                paragraph.&#xD;
&#xD;
        3. Data Collection:&#xD;
&#xD;
             -  Data colection forms will be dated and signed by the authorized principal&#xD;
                investigator.&#xD;
&#xD;
             -  Unknown data will be collected as &quot;NA&quot;(not available).&#xD;
&#xD;
             -  Unusual or extreme results, or that do not match the expected sequence will be&#xD;
                checked and corrected by initialing, signing and providing an explanation.&#xD;
&#xD;
             -  Laboratory results that exceed normal limits established by the laboratory of the&#xD;
                center, should be checked by the researcher and their significance will be noted&#xD;
                next to the data, by initialing and signing.&#xD;
&#xD;
        4. Statistical Analysis:&#xD;
&#xD;
             -  Baseline data will be analyzed using descriptive statistics and demographics (mean,&#xD;
                median, standard deviation, minimum, maximum, and number of valid cases) for&#xD;
                quantitative variables and absolute and relative frequencies for categorical&#xD;
                variables.&#xD;
&#xD;
             -  The primary efficacy objective is to determine the response rate of graft versus&#xD;
                host disease (confidence intervals 95%).&#xD;
&#xD;
             -  The primary safety objective is to determine the incidence of adverse events and&#xD;
                toxicity related to the administration of the CSM (confidence intervals 95%).&#xD;
&#xD;
             -  Secondary objectives: analyze overall survival and disease-free survival by the&#xD;
                Kaplan-Meier method.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>from infusion to 100 days after stem cell transplant</time_frame>
    <description>Infusion related.&#xD;
Infection Rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>efficacy</measure>
    <time_frame>Acute Graft-Versus-Host Disease period (100 days)</time_frame>
    <description>Acute Graft-Versus-Host Disease response rate.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Chronic Graft-Versus-Host Disease</condition>
  <arm_group>
    <arm_group_label>Allogenic Mesenchymal Stem Cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequential Infusion of Expanded in-Vitro Allogenic Mesenchymal Stem Cell (MSC). Dosage 0,7 x 10e6 MSC/Kg/dose (cumulative minimum dose: 2,8 x 10e6 CSM/Kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Allogenic Mesenchymal Stem Cell</intervention_name>
    <description>Expanded in-Vitro Allogenic Mesenchymal Stem Cell (authorized by Spain, &quot;Agencia Española de Medicamentos y Productos Sanitarios&quot; with number 06-076)</description>
    <arm_group_label>Allogenic Mesenchymal Stem Cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with hematologic malignancies who have undergone allogenic stem cell&#xD;
             transplantation and who are diagnosed with acute graft-versus-host-disease refractory&#xD;
             to first-line treatment.&#xD;
&#xD;
          -  Patients must have adequate cardiac function without evidence of uncontrolled&#xD;
             hypertension, congestive heart failure or myocardial infarction within 6 months prior&#xD;
             to the process.&#xD;
&#xD;
          -  Adequate pulmonary function with no evidence of severe obstructive or restrictive&#xD;
             pulmonary disease.&#xD;
&#xD;
          -  Be able to understand the information and sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with uncontrolled disease or in progress at the time of treatment.&#xD;
&#xD;
          -  Patients with uncontrolled bacterial, viral or fungal infection.&#xD;
&#xD;
          -  Patients with inadequate cardiac or pulmonary function.&#xD;
&#xD;
          -  Patients who do not have the required donor.&#xD;
&#xD;
          -  Women pregnant or at risk of pregnancy by inadequate contraceptive measures.&#xD;
&#xD;
          -  Patients who in the opinion of the investigator are not able to participate in the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fermín M Sánchez Guijo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Salamanca, Salamanca. Spain.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felipe Prosper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clínica Universitaria de Navarra, Spain.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduardo Olavarría, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Navarra, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rocío Parody, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen del Rocío, Seville, Spain.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmen Regidor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Puerta del Hierro, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmen Martínez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic i Provincial de Barcelona, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rodrigo Martino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de la Santa Creu i Sant Pau, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Antonio Pérez-Simón, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen del Rocío, Seville, Spain.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grupo Espanol de trasplantes hematopoyeticos y terapia celular</name>
      <address>
        <city>Madrid</city>
        <zip>28010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>September 30, 2013</study_first_submitted>
  <study_first_submitted_qc>September 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <last_update_submitted>September 30, 2013</last_update_submitted>
  <last_update_submitted_qc>September 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mesenchymal stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

